Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

(A joint stock limited company incorporated in the People's Republic of China with limited liability and carrying on business in Hong Kong as 國控股份有限公司)

(Stock Code: 01099)

ANNOUNCEMENT

PRINCIPAL FINANCIAL DATA OF SINOPHARM ACCORD

FOR THE THREE MONTHS ENDED 31 MARCH 2021

This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

Reference is made to the overseas regulatory announcement of Sinopharm Group Co. Ltd. (the "Company") dated 23 April 2021 (the "Announcement") in relation to the first quarterly report for the three months ended

31 March 2021 (the "Reporting Period") of China National Accord Medicines Corporation Ltd. ("Sinopharm Accord"), a subsidiary of the Company and whose A shares and B shares are listed on the Shenzhen Stock Exchange (stock code: 000028 for A shares; 200028 for B shares).

The board of directors of the Company would like to draw the attention of its shareholders and the public investors to the following principal unaudited financial data of Sinopharm Accord for the three months ended 31 March 2021 as set out in the Announcement.

1

PRINCIPAL ACCOUNTING DATA AND FINANCIAL INDICATORS OF SINOPHARM ACCORD

Unit: Yuan

Currency: RMB

Whether it has retroactive adjustment or restatement on previous accounting data or not

  • Yes √ No

Revenue

Net profit attributable to shareholders of the listed company

Net profit attributable to shareholders of the listed company after deducting non- recurring gains and losses

Changes of the

The Reporting Period

Same period of last year

Reporting Period over

the same period of last

year

16,049,966,325.75

12,824,196,278.66

25.15%

328,800,560.24

248,800,655.88

32.15%

321,593,612.98

241,724,850.95

33.04%

Net cash flow arising from operating activities

Basic earnings per share (Yuan/Share)

Diluted earnings per share (Yuan/Share)

Weighted average ROE

Total assets

Net assets attributable to shareholders of listed company

-306,748,999.24

0.77

0.77

2.33%

At the end of the Reporting Period

43,020,753,415.92

14,277,162,387.04

-688,273,848.63

55.43%

0.58

32.76%

0.58

32.76%

1.92%

Increased by 0.41

percentage point

Changes of the end of

At the end of last year

the Reporting Period

over the end of last year

39,594,533,471.65

8.65%

13,948,322,652.33

2.36%

By order of the Board

Sinopharm Group Co. Ltd.

Yu Qingming

Chairman

Shanghai, the PRC

23 April 2021

2

As at the date of this announcement, the executive directors of the Company are Mr. Yu Qingming and Mr. Liu Yong; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Ma Ping, Mr. Hu Jianwei, Mr. Deng Jindong, Mr. Wen Deyong, Ms. Guan Xiaohui and Ms. Feng Rongli; and the independent non-executive directors of the Company are Mr. Zhuo Fumin, Mr. Chen Fangruo, Mr. Li Peiyu, Mr. Wu Tak Lung and Mr. Yu Weifeng.

  • The Company is registered as a non-Hong Kong company under the Hong Kong Companies
    Ordinance under its Chinese name and the English name "Sinopharm Group Co. Ltd.".

3

Attachments

  • Original document
  • Permalink

Disclaimer

Sinopharm Group Co. Ltd. published this content on 23 April 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 23 April 2021 11:05:00 UTC.